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a b s t r a c t
Background: Licensed vaccines are urgently needed for emerging infectious diseases, but the nature of
these epidemics causes challenges for the design of phase III trials to evaluate vaccine efficacy.
Designing and executing rigorous, fast, and ethical, vaccine efficacy trials is difficult, and the decisions
and limitations in the design of these trials encompass epidemiological, logistical, regulatory, statistical,
and ethical dimensions.
Results: Trial design decisions are complex and interrelated, but current guidance documents do not lend
themselves to efficient decision-making. We created InterVax-Tool (http://vaxeval.com), an online, inter-
active decision-support tool, to help diverse stakeholders navigate the decisions in the design of phase III
vaccine trials.
InterVax-Tool offers high-level visual and interactive assistance through a set of four decision trees, guid-
ing users through selection of the: (1) Primary Endpoint, (2) Target Population, (3) Randomization Scheme,
and, (4) Comparator. We provide guidance on how key considerations – grouped as Epidemiological,
Vaccine-related, Infrastructural, or Sociocultural – inform each decision in the trial design process.
Conclusions: InterVax-Tool facilitates structured, transparent, and collaborative discussion of trial design,
while recording the decision-making process. Users can save and share their decisions, which is useful both
for comparing proposed trial designs, and for justifying particular design choices.
Here, we describe the goals and features of InterVax-Tool as well as its application to the design of a Zika
vaccine efficacy trial.
 2019 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
1. Background
Outbreaks or epidemics of emerging pathogens can pose a
major threat to public health and may lead to public health emer-
gencies (PHEs) [1]. Outbreaks can be unpredictable and often
accelerate quickly, as seen during the recent 2014–2016 Ebola
virus disease (EVD) and 2015–2016 Zika virus (ZIKV) epidemics.
Preparedness activities are needed to increase the effectiveness
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and speed of epidemic responses, including clinical research [2,3].
In particular, given the potential for safe and effective vaccines to
control or prevent future outbreaks, it is imperative that the inter-
national community become better prepared to develop and test
vaccines rapidly [2]. Even when candidate vaccines are available
in the early stages of an emerging outbreak, as was the case during
the 2014–2016 EVD epidemic, vaccine efficacy evaluation in phase
III trials must be planned and executed quickly to obtain the most
information possible. Design of such trials requires identification
and recruitment of participants at risk of infection; engagement
with local communities and national and international regulatory
authorities; and consideration of a trial design’s ethicality, feasibil-
ity, and acceptability [4].
Improving the design of vaccine efficacy trials can be achieved
by advance consideration of challenges that might arise in the con-
text of a PHE, and establishing how these challenges affect key
choices about trial design [5–9]. These challenges depend on fac-
tors such as the characteristics of the pathogen itself, the candidate
vaccine under study, local health systems infrastructure and labo-
ratory capacity, and the sociocultural context of the affected area
(s). Multi-faceted and interconnected considerations are complex,
and decision support tools that help clarify key issues can play
an important role in aiding the trial design process.
Navigating these considerations during emerging outbreaks
requires effective decision making because epidemic dynamics
can rapidly change. In particular, this difficult environment
requires clear understanding and communication of how decisions
on trial design affect downstream choices. Decision support sys-
tems have previously been developed to support clinical
decision-making [10], and to guide implementation of epidemic
interventions [11,12]. However, no decision support system has
been developed to assist in the design of phase III vaccine trials
during a PHE.
To address this issue, we have generated an interactive decision
support tool for phase III vaccine trial design, InterVax-Tool
(http://vaxeval.com). Through an interactive decision tree, which
is a branching diagram showing choices, InterVax-Tool steps
through key decision points, and demonstrates how particular
characteristics (such as those described above) affect those
decisions. InterVax-Tool is designed for use by diverse stakehold-
ers, including national and international authorities, public health
practitioners, policymakers, and others, and facilitates structured
dialogue amongst stakeholders using a common framework.
2. Implementation
While substantial research exists on vaccine efficacy trial design
[13], there is much less research on trial design for emerging infec-
tions, with the exception of novel work generated during the
2014–16 EVD outbreak [6,14–17]. Neither scientific literature nor
public health agency guidance documents lend themselves well
to urgent decision making: scientific literature is constantly chang-
ing and requires specialist knowledge for interpretation; and guid-
ance documents from public health agencies, due to their lengthy
and linear nature, can obscure the complex interdependencies
between decisions [18]. InterVax-Tool forms part of work on the
WHO Research & Development (R&D) Blueprint for preparedness
for epidemics [3,19] and was developed to harmonize with WHO
preparedness tools by linking with newly developed guidance on
trial design during outbreaks [4].
3. Structure
InterVax-Tool divides the design processes into four decision
topics: (1) Primary Endpoint, (2) Target Population, (3) Randomiza-
tion Scheme, and (4) Comparator; each has its own decision tree
(Supplementary Information). Decisions within each of these
topics are displayed as a hierarchy, giving a high-level view of
the key choices and trade-offs. Users proceed through the decision
topics, discussing and annotating each decision in turn.
InterVax-Tool gives support to these decisions with content that
describes4 categoriesof key considerations: (1) Epidemiology: patho-
gen transmission and epidemiology; (2) Infrastructure: health sys-
tems infrastructure; (3) Vaccine: characteristics of the vaccine
under test; and (4) Sociocultural: the sociocultural context of the
trial (Fig. 1). InterVax-Tool interactively displays all key considera-
tions that are relevant to each decision and how theymay affect that
Fig. 1. Schematic of InterVax-Tool’s decision process.Within each of four decision trees, users navigate a set of hierarchical decisions following guidance on how each of 14
key considerations affect the decision to pick one choice (blue rectangle) over another. During this process users take notes on the scenario under consideration as well as on
their justifications for the decisions chosen through the four decision trees.
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decision (Supplementary Information). This guidance includes cita-
tions both to scientific literature as well as to policy guidance docu-
ments [4]. InterVax-Tool allows users to assess implications for trial
design, to identify areaswheremore information is needed, andulti-
mately to make informed decisions on the trial design.
4. Four decision topics
4.1. Primary endpoint
The primary endpoint of a trial is the main result that is used to
determine efficacy, and for which participants are randomised,
and the trial powered. This decision topic allows the user to deter-
mine if an infection-related endpoint is chosen, and whether that
endpoint is quantified by a laboratory test or by participants meet-
ing a case definition, which could be general symptoms of disease
(such as feverwith rash), or a severe subset of the disease (for exam-
ple, encephalitis). Laboratory confirmation is themost common pri-
mary endpoint for vaccine trials. Users of InterVax-Tool then choose
how cases are ascertained from populations as either laboratory
confirmation or by clinical symptoms, and the assay used for detec-
tion (e.g. PCR, antibody, etc.) if laboratory confirmationwas selected.
4.2. Target population
The target population is the population or sub-population that
is enrolled in a trial. Users of InterVax-Tool are assumed to have
made decisions on where the trial will likely be held before using
the tool. The next decision is on the risk target for enrollment,
for example, are participants enrolled from the general population,
or in a particular geographic sub-areas (e.g. living close to a water
source), risk group (e.g. injecting drug users), or contact group (e.g.
family of a case). The aim of choosing a target population is to max-
imize the statistical power of the trial, and to evaluate safety and
efficacy in a representative group. The final decision in this tree
is whether the trial is responsive during enrollment or not. Respon-
sive trials identify target populations and recruit participants dur-
ing the outbreak. Responsive designs can increase power by
‘‘following” the outbreak dynamics but are logistically challenging.
4.3. Randomization scheme
Randomization is the process by which participants are sepa-
rated into those allocated the vaccine and those not. The first deci-
sion is either to randomize individuals or to randomize clusters of
individuals to receive the vaccine. Further questions in this deci-
sion tree are only used if the user selects cluster randomization.
The user must then choose between parallel and temporally-
varying cluster randomized (stepped wedge) designs. Clusters
may be stratified to allow risk-prioritized rollout of vaccination.
And finally, within-cluster individual randomization (two-tiered
randomization) can be selected.
4.4. Comparator
Events in the comparison group (often termed the ‘‘control
group”) are compared with the intervention or ‘‘vaccine group”
of the trial. Participants in the comparison group may be blinded
to their intervention status, which means they do not know if they
have received the vaccine or not. This can be done if the partici-
pants receive a sham vaccine or ‘‘placebo”. This vaccine can be
an active control, which is a real vaccine, but with no known
impact on the disease under study. If no placebo or active control
is used, then the participants know if they receive the vaccine or
not, and the design is an open-label trial. If blinding is used, if both
the participants and trial researchers do not know the status of
participants, the trial is double-blinded. Inverted single-blind can
be used, where the participants know if they have received the
active vaccine but investigators do not. The final decision is if the
comparison group receives the vaccine after a delay, or at the close
of the trial (or never). For example, delayed comparison was used
during the Ebola ça Suffit phase 3 vaccine trial in 2015–16 [20,21].
5. Usability
InterVax-Tool facilitates open decision-making, accountability,
and shareability by allowing users to take notes on their decisions
and on how each key consideration applies. Notes made on deci-
sions may reflect discussion about why a particular decision would
be made or the tradeoffs between different choices (Fig. 2) and are
anchored to that decision. Notes entered on key considerations are
available at each decision point. For instance, if users record notes
on a vaccine dose regimen while contemplating the primary end-
point, they will see and be able to update these same notes again
when considering how dose regimen might impact the choice of
comparator arm. This continuity in record-keeping generates a
comprehensive record of the epidemic scenario under examination
as well as justification for the best trial design(s). Scenarios and all
annotation can be saved to an online database and loaded later,
shared with others, or exported to a printable file.
InterVax-Tool works in settings with low bandwidth internet
access, and promotes user engagement through an interactive
user-friendly design [22]. It is completely free to use and open to
all users online. Completed trees are stored in a database and
retrieved using an email address and PIN code.
A five-minute video tutorial gives an introduction to the user
interface. InterVax-Tool also contains a completed tree on ZIKV
vaccine trial design scenarios. This tree, plus completed trees
shared by other users will be an excellent resource when using
InterVax-Tool for capacity building in vaccine trial design.
The WHO R&D Blueprint working group on phase 3 vaccine tri-
als also generated a detailed guidance document on vaccine trial
design [4] which is integrated with InterVax-Tool [23].
6. Case Study: Zika vaccine efficacy trial design
We piloted InterVax-Tool at the WHO Workshop on ‘‘Efficacy
trials of ZIKV Vaccines: endpoints, trial design, site selection” in
June 2017 to assist in the design of ZIKV vaccine efficacy trials
[24]. At this meeting, a group of 30 experts used InterVax-Tool to
discuss and refine options for potential phase III vaccine trials in
Latin America. We displayed VaxEval.com on a projector, and used
the site like a decision-making agenda, taking each decision point
in turn. To lead the structured discussion we had a facilitator who
was familiar with the website, key questions in trial design, and
the scenario under study. The facilitator then prompted the key
considerations for each decision to the group, and made sure these
considerations were covered.
In future, we recommend a separate note-taker, who can input
those live into the site during the discussion. At the end of each
decision point, the facilitator should be sure to summarize and
reach consensus, so that all participants are satisfied with the deci-
sion chosen and the information recorded into the site. Note that
multiple trees can be used if needed, for example if some decisions
lead to different preferred trial designs.
By using InterVax-Tool, the participants quickly focused their
discussion on the three key areas where more information is
needed to inform ZIKV vaccine trial planning: (1) the ability of
serological assays to identify specific past flavivirus infections, i.e.
determining serological positivity for ZIKV against a background
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of potential cross-reactivity from dengue virus (DENV; a related
flavivirus); (2) forecasted or expected incidence required for feasi-
ble sample sizes; and (3) whether to use laboratory-confirmed
ZIKV infection (whether asymptomatic or symptomatic) or
laboratory-confirmed symptomatic Zika disease as the primary
endpoint. The discussion quickly clarified that severe complica-
tions from ZIKV infection, such as Zika congenital syndrome or
Guillain-Barré syndrome, were rare outcomes and, therefore, infea-
sible as primary endpoints. The ZIKV vaccine pipeline had 45 vac-
cine candidates at the time of the meeting, so participants agreed
to delay focus on vaccine characteristics until candidate vaccines
were approaching phase III trials. Meeting attendees agreed that
the InterVax-Tool allowed a diverse group of experts to quickly
narrow down the range of design possibilities and agree on impor-
tant knowledge gaps that needed further attention.
7. Discussion
We created a web-based interactive decision tree tool,
InterVax-Tool, to support decision making on vaccine trial design.
By focusing users on the key decisions, trade-offs, and interdepen-
dencies, InterVax-Tool allows multidisciplinary users to quickly
identify the key issues for each outbreak scenario and thereby
assist the response to public health emergencies. It allows sharing
and documentation of decision processes and provides scientific
content to aid in the decision-making process.
InterVax-Tool is not intended to give a single answer on the
optimal trial design for a given scenario, but rather to promote
organized, efficient, and transparent discussion. In fact, the tool
discourages the notion that there may be a single ideal design for
any particular scenario and encourages participants to consider
tradeoffs between multiple trial design decisions.
Additionally, a key component of vaccine trials is sample size
calculations. The diversity and complexity of possible trial designs
that can be generated using InterVax-Tool make generalizing about
sample sizes very difficult, and we do not think this could be pre-
sented in a user-friendly way alongside the underlying decision
tree process. Sample size calculations are discussed in the linked
WHO Blueprint Working Group publication [4] and in textbooks
on trial design [13]. We suggest that once feasible trial designs
Fig. 2. Screenshot of InterVax-Tool at http://vaxeval.com. The decision tree with decisions and notes is presented on the top portion. The lower portion provides content on
how relevant key considerations impact the active decision in the tree and provides the opportunity for users to take notes on each key consideration, building a description
of the scenario during the process.
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are identified, users of InterVax-Tool could consult with statisti-
cians and epidemiologists to generate required sample sizes.
The guidance presented within InterVax-Tool reflects the col-
lective expertise of this working group and its attempt to summa-
rize the scientific literature on vaccine efficacy trial design. We
encourage user feedback so that content can be updated to reflect
the state-of-the-art on all facets of trial design.
Because InterVax-Tool is organized in a hierarchical decision
tree framework, decisions are reflected as discrete choices between
two or more options. In reality, some decisions may fall along a
spectrum and not all categories are mutually exclusive. Nonethe-
less, the categorization scheme used encourages discourse and
planning, though it simplifies some aspects of trial design.
Further, because InterVax-Tool aims to avoid user fatigue, some
trial design options were excluded (e.g., factorial design and
interim analysis options). The guidance within InterVax-Tool pro-
vides ample reference to the scientific literature on these topics
as well as to the complementary, comprehensive WHO guidance
document [4].
An important feature of the tool is the ability to transmit anno-
tated decision trees and design justifications between users. For
example, investigators could use the tool to provide their justifica-
tion for a particular trial design to regional public health authorities.
The tool may be similarly useful to vaccine manufacturers thinking
about trial scenarios for a vaccine early in the pipeline. Finally, the
tool may be useful in capacity building, providing students of trial
design and emerging infections with a lens into this complex deci-
sion process. The conceptual design of this tool may be applicable
to many other aspects of public health or other disciplines in which
rapid, transparent, highly technical, and interdisciplinary decision
making is necessary to address an urgent problem.
8. Conclusions
Intervax-Tool is decision-support tool for designing vaccine effi-
cacy trials during emerging disease epidemics and outbreaks. It is
web-based, interactive, and contains up-to-date scientific informa-
tion to support real-time decision-making on trial design. Interac-
tive tools are needed to demonstrate the complex
interdependencies in trial design choices, and how many factors
can affect trial feasibility.
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